



Advancing Research. Improving Lives.™

TO: ALL PRINCIPAL INVESTIGATORS, NURSES AND DATA MANAGERS

FROM: PROTOCOL DEPARTMENT

DATE: August 17, 2026

RE: GOG-0213 PROTOCOL – TERMINATION

“A PHASE III RANDOMIZED CONTROLLED CLINICAL TRIAL OF CARBOPLATIN AND PACLITAXEL (OR GEMCITABINE) ALONE OR IN COMBINATION WITH BEVACIZUMAB (NSC #704865, IND #113912) FOLLOWED BY BEVACIZUMAB AND SECONDARY CYTOREDUCTIVE SURGERY IN PLATINUM-SENSITIVE, RECURRENT OVARIAN, PERITONEAL PRIMARY AND FALLOPIAN TUBE CANCER. NCI-SUPPLIED AGENTS: BEVACIZUMAB (NSC #704865, IND #113912)”

NCI Version: November 16, 2018

Study Chair: Robert L. Coleman, M.D.; email: robert.coleman@usoncology.com

Per action of the GYN Cancer Committee, GOG-0213 is terminated effective August 17, 2026. All data collection is complete, and the trial may be closed with your IRB.